Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
用化療治療乳腺癌的大麻素：迷幻生物技術公司簽署了6100萬美元的專利方法許可協議
Enveric Biosciences (NASDAQ:ENVB), a Nasdaq-listed psychedelics biotech firm, has entered into a non-binding term sheet with an undisclosed biotech company (licensee) for an exclusive license to two patented methods aimed at treating breast cancer and other cancers. These methods utilize cannabinoids in combination with chemotherapeutic drugs.
在納斯達克上市的迷幻藥生物技術公司Enveric Biosciences（納斯達克股票代碼：ENVB）已與一家未公開的生物技術公司（被許可人）簽訂了一份不具約束力的條款表，以獲得兩種旨在治療乳腺癌和其他癌症的專利方法的獨家許可。這些方法將大麻素與化療藥物聯合使用。
As per the agreement, the licensee will obtain an exclusive, global license to these methods, along with any devices and drugs developed to implement them. The licensee will also take on all future preclinical and clinical development responsibilities on a royalty-bearing basis for both human and animal pharmaceutical applications.
根據協議，被許可方將獲得這些方法以及爲實施這些方法而開發的任何設備和藥物的獨家全球許可。被許可方還將承擔所有未來人類和動物藥物應用的臨床前和臨床開發職責，並以特許權使用費爲基礎。
Subject...
在...
登入免費觀看全文
登入/註冊